New Delhi:Pharma leader Sun Pharmaceutical Industries has recorded a Rs 3,118 crore net profit in Q2 FY26, up 2.56 percent, as India and emerging market sales drove growth. The company had reported a net profit of Rs 3,040 crore in the same quarter last fiscal. The Mumbai-based company’s revenue from operations climbed to Rs 14,405 crore, compared to Rs 13,264 crore in the same period last fiscal. "India, emerging markets, and the Rest of the World (market) led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability," Kirti Ganorkar, Managing Director of the company, said. Emerging Markets formulations sales were USD 325 million for Q2FY26, up by 10.9% and accounted for 19.7% of total consolidated sales. For the first half, sales were US$ 623 million, growing by 8.0% over same period last year. Formulation sales in Rest of World (RoW) markets were USD 234 million for Q2FY26, up by 17.7% and accounted for 14.2% of total consolidated sales for the quarter. For the first half, sales were US$ 453 million, up by 16.6% over same period last year. Global Innovative Medicines sales were US$ 333 million for Q2FY26, up 16.4% over Q2 last year and accounted for 20.2% of total consolidated sales for the quarter. For the first half, sales were US$ 644 million, up by 16.6% over same period last year. During the quarter, Leqselvi was launched in the US for the treatment of severe alopecia areata and has received encouraging response from the prescribers and patients. For Q2FY26, external sales of API were Rs. 4,299 million, down by 19.5%. For the first half, API sales were Rs. 9,702 million, a decline of 5.7% over the same period last year.